LONDON (Alliance News) - Futura Medical PLC on Wednesday said its MED2002 erectile dysfunction gel achieved its primary endpoint in its recent efficacy study.
Futura said MED2002 successfully demonstrated efficacy, safety and speed of onset in the study and showed a statistically significant improvement in treating erectile dysfunction compared to a placebo.
The safety profile of the gel also indicates MED2002 will support a significant unmet area of need in treating erectile dysfunction, notably those sufferers unable to be prescribed PDE5 inhibitors due to clashes with other medicines.
The results from the study will form the basis for commercialisation of MED2002, which shares the same active ingredient at Futura's CSD500 erectogenic condom.
"The headline data from the study indicate that we have a breakthrough ED product that is not only effective but may also combine potentially the world's fastest speed of onset for an ED treatment with a very favourable safety profile," said Futura Chief Executive James Barder.
"We will carry out further analysis of the results in the next few days and are very excited by the commercial potential of this product," Barder added.
The company will provide further analysis of the test results with its results announcement on Tuesday next week.
Futura shares rocketed at the open on Wednesday, up 58% to 45.00 pence.
By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
Futura Medical (FUM)